Rheumatology — Medicare Part B billing by state
343 physician groups whose primary specialty is Rheumatology billed $908.0M to Medicare fee-for-service in 2023.
Calendar year 2023 · Medicare fee-for-service Part B
You're viewing calendar year 2023. State market links open the latest data year.
On this page: Billing by state · Top codes
Medicare billing by state
| State | Standardized payments | Medicare payments | Groups | Pay / group | Services | Benef.-episodes | Svc / group |
|---|---|---|---|---|---|---|---|
| Florida | $111.3M | $111.0M | 34 | $3.3M | 10.3M | 205K | 303K |
| Texas | $82.4M | $80.9M | 50 | $1.6M | 7.2M | 230K | 144K |
| California | $73.8M | $75.4M | 39 | $1.9M | 5.8M | 202K | 148K |
| Pennsylvania | $57.6M | $58.2M | 17 | $3.4M | 3.9M | 152K | 227K |
| Arizona | $47.8M | $47.3M | 8 | $5.9M | 3.9M | 110K | 490K |
| North Carolina | $42.6M | $42.1M | 18 | $2.3M | 3.4M | 90,714 | 189K |
| New York | $36.3M | $36.9M | 19 | $1.9M | 2.4M | 131K | 124K |
| South Carolina | $35.6M | $34.8M | 9 | $3.9M | 2.9M | 64,579 | 322K |
| New Jersey | $33.9M | $34.1M | 13 | $2.6M | 3.2M | 57,469 | 245K |
| Maryland | $29.3M | $29.6M | 11 | $2.7M | 2.3M | 78,916 | 207K |
| Oklahoma | $29.3M | $28.3M | 7 | $4.0M | 2.3M | 74,871 | 322K |
| Virginia | $28.9M | $28.8M | 14 | $2.1M | 2.6M | 48,429 | 188K |
| Alabama | $25.3M | $24.7M | 10 | $2.5M | 1.7M | 63,797 | 169K |
| Missouri | $22.7M | $22.2M | 7 | $3.2M | 1.8M | 58,852 | 250K |
| Tennessee | $21.8M | $21.3M | 12 | $1.8M | 2.0M | 50,043 | 166K |
| Kentucky | $20.2M | $19.8M | 13 | $1.5M | 2.1M | 26,933 | 159K |
| Georgia | $19.5M | $19.2M | 13 | $1.5M | 1.5M | 58,805 | 118K |
| Louisiana | $17.7M | $17.3M | 6 | $2.9M | 1.5M | 44,365 | 254K |
| Ohio | $17.6M | $17.4M | 8 | $2.2M | 1.2M | 56,241 | 154K |
| Kansas | $16.0M | $15.9M | 5 | $3.2M | 1.4M | 34,432 | 285K |
| Michigan | $14.0M | $13.8M | 14 | $982K | 1.0M | 24,493 | 74,677 |
| Indiana | $13.8M | $13.5M | 10 | $1.4M | 1.2M | 30,149 | 118K |
| Illinois | $10.8M | $10.8M | 7 | $1.5M | 998K | 30,159 | 143K |
| Minnesota | $10.5M | $10.5M | 5 | $2.1M | 677K | 25,964 | 135K |
| Idaho | $9.8M | $9.6M | 3 | $3.2M | 898K | 21,951 | 299K |
| Oregon | $9.7M | $9.6M | 6 | $1.6M | 716K | 15,775 | 119K |
| Colorado | $8.3M | $8.3M | 5 | $1.7M | 667K | 12,675 | 133K |
| Wisconsin | $8.2M | $8.1M | 5 | $1.6M | 581K | 29,819 | 116K |
| Nebraska | $8.1M | $8.0M | 2 | $4.0M | 885K | 28,772 | 443K |
| Arkansas | $7.6M | $7.5M | 4 | $1.9M | 579K | 8,628 | 145K |
| Iowa | $7.4M | $7.3M | 2 | $3.7M | 558K | 35,039 | 279K |
| Washington | $6.3M | $6.3M | 5 | $1.3M | 384K | 19,503 | 76,729 |
| Mississippi | $5.3M | $5.2M | 4 | $1.3M | 575K | 20,993 | 144K |
| Hawaii | $4.1M | $3.9M | 1 | $3.9M | 313K | 12,215 | 313K |
| Massachusetts | $4.1M | $4.1M | 4 | $1.0M | 234K | 21,813 | 58,528 |
| Delaware | $3.4M | $3.4M | 3 | $1.1M | 322K | 4,590 | 107K |
| New Mexico | $2.2M | $2.1M | 3 | $705K | 120K | 2,851 | 39,902 |
| Rhode Island | $2.1M | $2.1M | 2 | $1.0M | 218K | 3,035 | 109K |
| Nevada | $1.9M | $1.8M | 5 | $365K | 170K | 4,193 | 33,915 |
| Utah | $1.9M | $1.9M | 1 | $1.9M | 376K | 981 | 376K |
| District of Columbia | $1.6M | $1.7M | 3 | $553K | 148K | 6,179 | 49,353 |
| Connecticut | $1.5M | $1.5M | 7 | $215K | 104K | 4,034 | 14,796 |
| New Hampshire | $1.2M | $1.2M | 3 | $387K | 78,473 | 684 | 26,158 |
| Maine | $513K | $514K | 1 | $514K | 75,034 | 2,909 | 75,034 |
| PR | $153K | $152K | 2 | $76K | 3,831 | 276 | 1,916 |
| Wyoming | $39K | $35K | 1 | $35K | 418 | 240 | 418 |
| West Virginia | $27K | $28K | 1 | $28K | 279 | 144 | 279 |
Need this specialty's market in one document?
Register your interestEach group carries one specialty label — the specialty most common among its clinicians in CMS's Doctors and Clinicians register — so every figure on this page counts groups, not individual clinicians. An organization's entire Medicare billing is credited to that one label, so a specialty's totals reflect how organizations are labeled, not the specialty of each service; large multi-specialty organizations — where no single specialty is a majority of the clinicians — account for much of the volume shown under many specialties. Totals include only volume that can be credited to a single group; clinicians registered with more than one group are left out of group totals and shown as “—” elsewhere on Nevvi. Clinicians not registered with any group, and groups without a specialty label, are also not included. A group is counted in every state its clinicians bill Medicare from, so state figures overlap and never sum to the national figure.
All figures are Medicare fee-for-service Part B only; Medicare Advantage claims are not included. Cross-state comparisons use standardized payments, which remove regional differences in what Medicare pays; services without a standardized amount — mainly Part B drugs — are not in that column, and the Medicare payments column shows what Medicare actually paid. Beneficiary counts are beneficiary-episodes: one person treated in more than one setting or state is counted in each.
Top codes by Medicare payments CY2023
2 more CPT-coded procedures — shown with a trial or subscription, under AMA licensing.
| Code | Medicare payments | Services | Largest state markets |
|---|---|---|---|
| J0129 · Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | $205.9M | 6.2M | FLTXCAPAAZ |
| J1602 · Injection, golimumab, 1 mg, for intravenous use | $97.2M | 9.4M | FLTXCAPAAZ |
| J0717 · Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | $95.5M | 24.6M | FLTXCAPAAZ |
| J0897 · Injection, denosumab, 1 mg | $94.5M | 5.2M | FLTXCAPAAZ |
| J3262 · Injection, tocilizumab, 1 mg | $70.1M | 15.2M | FLTXCAPAAZ |
| J1745 · Injection, infliximab, excludes biosimilar, 10 mg | $56.0M | 2.2M | FLTXCAPAAZ |
| J3111 · Injection, romosozumab-aqqg, 1 mg | $39.6M | 5.0M | FLTXCAPAAZ |
| J9312 · Injection, rituximab, 10 mg | $34.6M | 560K | FLTXCAPAAZ |
| J1439 · Injection, ferric carboxymaltose, 1 mg top by services | $342K | 395K | FLTXCAPAAZ |